Intestinal GLP-1 and satiation: from man to rodents and back
Disclosures: Brian Davis: Nothing to Disclose, Kai-Chun Lin: Nothing to Disclose, Jasmohan Bajaj: Bausch: Grant/Research Support, Sequana: Grant/Research Support, Cosmo: Grant/Research Support, Grifols: Grant/Research Support, Shalini Prasad: Nothing to Disclose, Sriram Muthukumar: Nothing to Disclose 2258 REDUCTION OF UNNECESSARY CT HEAD USE IN CIRRHOTIC PATIENTS PRESENTING WITH HEPATIC ENCEPHALOPATHY Vivienne Nguyen 1 , 1 Sir Charles Gairdner Hospital Background: Hepatic encephalopathy (HE) is a neuropsychiatric complication often associated with cirrhosis, manifesting as a wide spectrum of changes in mental state
Another area of interest for GLP-1 agents is their potential use in treating polycystic ovarian syndrome (PCOS)
Online posts are self-reported and cannot always be independently verified
But simply offering GLP-1 medications wont guarantee revenue
This report explains each medication in detail